ASHP Best Practice Award 2023: Real-World Clinical Impact of an In-House Dihydropyrimidine Dehydrogenase (DPYD) Genotyping Test on Fluoropyrimidine Dosing and Toxicity at a Multisite Cancer Center

ASHPOfficial

In this episode, the team from the Atrium Health System discuss their award-winning submission to the ASHP Best Practices. They will share how their program implemented a novel pharmacist-led DPYD testing program with CDS integration and demonstrated pre-treatment testing with genotype-guided fluoropyrimidine dosing improves patient safety by mitigating severe toxicities and hospitalizations in DPYD variant carriers.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.